1-(Cyclopropylmethyl)piperazine → 4-(8-((4-(cyclopropylmethyl)piperazin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine

HRID 1923027

반응식

HRID 1923027 반응식
Br[CH2:2][C:3]1[N:4]([CH3:28])[C:5]2[C:10]([N:11]=1)=[C:9]([N:12]1[CH2:17][CH2:16][O:15][CH2:14][CH2:13]1)[N:8]=[C:7]([N:18]1[C:22]3[CH:23]=[CH:24][CH:25]=[CH:26][C:21]=3[N:20]=[C:19]1[CH3:27])[N:6]=2.[CH:29]1([CH2:32][N:33]2[CH2:38][CH2:37][NH:36][CH2:35][CH2:34]2)[CH2:31][CH2:30]1>>[CH:29]1([CH2:32][N:33]2[CH2:38][CH2:37][N:36]([CH2:2][C:3]3[N:4]([CH3:28])[C:5]4[C:10]([N:11]=3)=[C:9]([N:12]3[CH2:17][CH2:16][O:15][CH2:14][CH2:13]3)[N:8]=[C:7]([N:18]3[C:22]5[CH:23]=[CH:24][CH:25]=[CH:26][C:21]=5[N:20]=[C:19]3[CH3:27])[N:6]=4)[CH2:35][CH2:34]2)[CH2:31][CH2:30]1

참가 물질

3

반응물 2

HCID 9658751-(Cyclopropylmethyl)piperazineHCID 596058124-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine

생성물 1

HCID 596057104-(8-((4-(cyclopropylmethyl)piperazin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine

실험 절차

4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine (50 mg) was reacted with 1-(cyclopropylmethyl)piperazine via General Procedure E to give 23.5 mg of 277 following reverse phase purification. MS (Q1) 502.3 (M)+

후처리

  1. customto give
  2. custom23.5 mg of 277 following reverse phase purification

출처 및 근거

ORD 기록
ord-5b19a809e15d45eba777766f48717173
출처 데이터셋
uspto-grants-2012_05
특허 번호
US08173650B2

연결된 노트

불러오는 중…